Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph phase_2
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Terminated(1)
Other(1)

Detailed Status

Recruiting2
Withdrawn1
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

withdrawn120%
recruiting240%
unknown120%
active_not_recruiting120%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_2

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

NCT05568212
withdrawnphase_2

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

NCT06120972
recruitingphase_2

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

NCT06739395
active_not_recruitingphase_1

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

NCT05358639
unknownphase_2

The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation

NCT05167175

Clinical Trials (5)

Showing 5 of 5 trials
NCT05568212Phase 2

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Recruiting
NCT06120972Phase 2

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Withdrawn
NCT06739395Phase 2

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting
NCT05358639Phase 1

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Active Not Recruiting
NCT05167175Phase 2

The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5